Champions Oncology, Inc. (CSBR)

Market Cap	102.81M
Revenue (ttm)	53.57M
Net Income (ttm)	-598,000
Shares Out	13.70M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	39.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,019
Open	7.64
Previous Close	7.55
Day's Range	7.15 - 7.66
52-Week Range	3.60 - 7.85
Beta	0.47
Analysts	Strong Buy
Price Target	8.00 (+6.6%)
Earnings Date	Dec 11, 2024

About CSBR

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 1986
• Employees: 210
• Stock Exchange: NASDAQ
• Ticker Symbol: CSBR
• Website: https://www.championsoncology.com

Financial Performance

In 2024, Champions Oncology's revenue was $50.16 million, a decrease of -6.90% compared to the previous year's $53.87 million. Losses were -$7.28 million, 36.4% more than in 2023.

Analyst Forecast

According to one analyst, the rating for CSBR stock is "Strong Buy" and the 12-month stock price forecast is $8.0.

Price Target

$8.0

(6.60% upside)

Analyst Consensus: Strong Buy